<DOC>
	<DOCNO>NCT02947880</DOCNO>
	<brief_summary>During previous therapeutic trial , investigator show bumetanide improve significantly autism . This trial show therapeutic response obtain 75 % case . These first result reinforce study lead adult patient eye track measurement well functional MRI show diminution response time modification ( amplification ) cerebral response emotion recognition test . Finally , investigator confirm physiological mechanism behind action bumetanide study two mouse model autism .</brief_summary>
	<brief_title>Evaluation Efficiency Treatment BUMETANIDE Autistic Children With Known Ethiology</brief_title>
	<detailed_description />
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Bumetanide</mesh_term>
	<criteria>Children teenager age 5 age 17 , diagnosis typical autism Asperger syndrome accord criterion diagnosis WHO 's classification ( CIM10 ) , With know etiology , Patients CARS result strictly Superior equal 30 , Of parent give free , informed write consent , Affiliated beneficiary French social security . Patients treatment inlet diuretic either time study , Patients electrolytic disorder , Patients know hypersensitivity sulfa drug , Patients hepatic renal failure , Patients epilepsy control treatment ( comitial crisis past 6 month time trial start despite treatment ) , Patients treatment psychotropic exception make melatonin , Allergy bumetanide one excipients , Patient treatment lithium , diphemanil , erythromycin IV , halofantrine , pentamidine , sultopride , vincamine , aminoglycoside , Pregnant lactate woman . Secondary exclusion criterion : QT prolongation notice ECG Day0 , Anomaly biological check ( Day 0 ) make include patient would contraindicate prescription bumetanide , Patients CARS result strictly inferior 30 .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>autism , Bumetanide</keyword>
</DOC>